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ABSTRACT
Dogs with X-linked severe combined immunodeficiency (XSCID) can be successfully treated by bone marrow
transplants (BMT) resulting in full immunologic reconstitution and engraftment of both donor B and T cells
without the need for pretransplant conditioning. In this study, we evaluated the T cell diversity in XSCID dogs
4 months to 10.5 years following BMT. At 4 months posttransplantation, when the number of CD45RA
(naïve) T cells had peaked and plateaued, the T cells in the transplanted dogs showed the same complex,
diverse repertoire as those of normal young adult dogs. A decline in T cell diversity became evident approx-
imately 3.5 years posttransplant, but the proportion of V families showing a polyclonal Gaussian spectratype
still predominated up to 7.5 years posttransplant. In 2 dogs evaluated at 7.5 and 10.5 years posttransplant,
>75% of the V families consisted of a skewed or oligoclonal spectratype that was associated with a CD4/CD8
ratio of<0.5. The decline in the complexity of T cell diversity in the transplanted XSCID dogs is similar to that
reported for XSCID patients following BMT. However, in contrast to transplanted XSCID boys who show a
significant decline in their T cell diversity by 10 to 12 years following BMT, transplanted XSCID dogs maintain
a polyclonal, diverse T cell repertoire through midlife.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Severe combined immunodeﬁciency (SCID) is a
eterogenous group of diseases characterized by the
nability to mount humoral and cell-mediated immune
esponses and is invariably fatal within the ﬁrst 2 years
f life [1,2]. X-linked severe combined immunodeﬁ-
iency (XSCID) is the most common form of the
isease representing approximately 50% of all human
CID [2,3]. XSCID is caused by mutations in the
ommon gamma (c) subunit of the receptors for
L-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (reviewed in
4,5]). Thus, the XSCID phenotype is the complex iesult of multiple cytokine defects. The shared usage
f the c by receptors for growth factors that are
ritical for normal B, natural killer (NK), and T cell
evelopment and function explains the profound im-
unologic abnormalities and clinical severity of the
isease.
Since the ﬁrst successful HLA-identical bone mar-
ow transplant (BMT) in a boy with XSCID in 1968
6], BMT has become the treatment of choice for all
orms of SCID [3,7-10]. SCID patients receiving a
istocompatible (HLA-identical) BMT have 90%
ong-term survival rates [3,8,9]. However, the major-
ty of patients do not have a histocompatible donor.
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W. Vernau et al.1006aploidentical BMT with T cell depletion to prevent
atal graft-versus-host disease (GVHD) has become
he standard therapy for SCID patients who lack a
istocompatible donor [3,7-13]. Although T cell de-
letion makes BMT possible for virtually all SCID
atients, long-term immune reconstitution and sur-
ival is less favorable than after histocompatible BMT,
anging from 60% to 70% [8,9]. The most common
mmunologic problem in human XSCID patients fol-
owing BMT is poor humoral immune reconstitution.
s a result, many patients need to be maintained
ndeﬁnitely on prophylactic immune globulin (IVIG)
herapy [7-9,14,15].
Two recent studies have evaluated thymic func-
ion (thymopoiesis) and T cell diversity in SCID
atients for up to 18 years after BMT without any
retransplant conditioning [16,17]. The majority were
ither XSCID or Jak3-deﬁcient patients. Most had
eceived T cell-depleted, haploidentical transplants.
hese studies showed that within 6 to 12 months
osttransplant there is a robust regeneration of naïve
CD45RA) peripheral T cells with a highly diverse,
olyclonal T cell repertoire that develops through
ctive thymopoiesis as measured by T cell receptor
xcision circle (TREC) analysis. However, between 10
nd 12 years posttransplant there was little evidence of
ctive thymopoiesis as demonstrated by extremely low
evels of naïve peripheral T cells and almost undetect-
ble TREC levels. These changes are accompanied by
igniﬁcant skewing of the T cell repertoire.
Our laboratory has identiﬁed and characterized an
SCID resulting from distinct c mutations in basset
ound and cardigan Welsh corgi dogs that has a clin-
cal and immunologic phenotype virtually identical to
uman XSCID [18-22]. We have shown that XSCID
ogs can be successfully transplanted with unfraction-
ted bone marrow or highly puriﬁed bone marrow
D34 cells from histocompatible normal donors re-
ulting in full immunologic reconstitution and en-
raftment of both donor B and T cells without the
eed for pretransplant conditioning [23-25]. In this
tudy, we describe the T cell diversity in XSCID dogs
months to 10.5 years following nonconditioned,
istocompatible BMT.
ATERIALS AND METHODS
ogs
The XSCID dogs used in this study were derived
rom a breeding colony of XSCID dogs with c mu-
ations consisting of either a 4-bp deletion in exon 1
basset mutation, R dogs) or single nucleotide inser-
ion in exon 4 (corgi mutation, X dogs) [18,19,26].
ffected dogs were diagnosed shortly after birth by
he absence of peripheral T cells as determined by
ow cytometry and conﬁrmed by a speciﬁc PCR- iased mutation detection assay for each mutation us-
ng DNA isolated from whole blood [20,23,26]. DLA-
dentical donors for transplantation were determined
y PCR assay for highly polymorphic MHC class I
nd class II microsatellite marker polymorphisms [27].
one Marrow Preparation
Bone marrow cells were collected from the donors
ollowing euthanasia by removing a segment of the
emur, ﬂushing the marrow into a sterile Petri dish
ontaining HBSS without calcium and magnesium
Mediatech, Fisher Scientiﬁc, Philadelphia, PA), and
incing into a single cell suspension [23,24]. The
esulting suspension was ﬁltered through a sterile
0-m cell strainer (Becton Dickinson, Franklin
akes, NJ), and washed twice with HBSS. Following
ltration, the cells were centrifuged and resuspended
n ammonium chloride lysing buffer (Sigma Chemical,
t. Louis, MO) to remove red blood cells (RBCs).
fter a 5-minute incubation on ice, the cells were
ashed twice in HBSS and the ﬁnal pellet resus-
ended in sterile saline.
solation of Bone Marrow CD34 Cells
The resulting bone marrow cell suspension was
esuspended at a ﬁnal concentration of 1  108
ells/mL in a PBS solution containing 2 mmol/L
DTA, 0.1% BSA, and anticanine CD34 antibody
H6 [28] at 40 g/mL. Cells were resuspended and
hen labeled with the secondary antimouse IgG
ACS magnetic microbeads according to the manu-
acturer’s protocol (Miltenyi, Auburn, CA). Labeled
ells were selected on varioMACS columns as recom-
ended by the manufacturer. Aliquots of positively
elected cells were analyzed by ﬂow cytometry to
etermine the purity of the eluted cells.
one Marrow Transplantation
XSCID dogs had BMTs with cells from DLA-
dentical, normal littermate donors between 1 and 2
eeks of age without any pretransplant conditioning.
ntreated nucleated bone marrow cells, containing
1% mature T cells, were administered intravenously
t a dose of 1.0 to 1.5  108 nucleated cells/kg. Dogs
ransplanted with CD34 bone marrow cells, purity
95%, received doses of 5 to 35  106 CD34 cells/
g. The transplanted dogs were reared in a conven-
ional environment and maintained on prophylactic
ntibiotics for the ﬁrst 2 to 3 months following trans-
lantation. None of the dogs received intravenous
amma globulin because of its lack of availability for
ogs.
low Cytometry
Peripheral blood mononuclear cells (PBMC) were
solated from heparinized whole blood by centrifuga-
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T Cell Diversity in BMT XSCID Dogs 1007ion over a discontinuous density gradient ofHypaque-
icoll and stained for ﬂow cytometric analysis as pre-
iously described [21,23]. Analysis gates were adjusted
o 1% positive staining with isotype controls. For each
ample, 10,000 cells were analyzed using a Becton
ickinson FACSCalibur (Becton Dickinson, San
ose, CA). The murine monoclonal antibodies (mAb)
sed in this study were CA17.3G9, canine CD3;
A13.1E4, canine CD4; CA9.JD3, canine CD8; and
A4.1D3, canine CD45RA [29,30]. FITC conjugated
(ab=)2 goat antidog IgG (heavy- and light-chain spe-
iﬁc) was purchased from Cappel (Durham, NC).
ITC- and PE-labeled secondary antibodies were
urchased from Fisher Scientiﬁc.
roliferation Assays
The response of peripheral blood lymphocytes to
n vitro mitogenic stimulation with PHA-P (5 g/mL;
igma,) was performed as previously described using
ncorporation of tritiated thymidine [21,23]. The re-
ults are expressed as counts per minute (CPM).
ssessment of Antigen-Specific IgG
ntibody Response
Between 4 and 6 months posttransplantation dogs
ere immunized intramuscularly with 0.5 mL tetanus
oxoid (Lederle, Pearl River, NY). Animals were re-
mmunized with tetanus toxoid 2 and 4 weeks after the
nitial immunization. IgG-speciﬁc tetanus toxoid-spe-
iﬁc antibody was determined using an enzyme linked
mmunosorbent assay (ELISA) [25]. The results are
xpressed as percent of response of normal dogs.
CR V CDR3-Size Spectratyping
We have recently cloned and sequenced 43 differ-
nt canine TCR V-D-J sequences and conﬁrmed
heir speciﬁcity by sequence homology analysis with
nown TCR VDJ region sequences from other spe-
ies (manuscript in preparation). Twenty-three dis-
inct TCR V segments were identiﬁed that com-
rised 18 different families (80% homology at the
ucleotide level). The TCR V families were arbi-
rarily assigned numbers from BV1 to BV18, begin-
ing with families that contained the greatest number
f sequences, and numbered consecutively. Unique
embers of the same family were designated by as-
igning an additional consecutive number, for exam-
le, BV3.1, BV3.2, and BV3.3.
PCR primers were selected using the DNAstar
uite of sequence analysis tools. Forward primers lo-
ated in the V region were selected to prime at
egions of dissimiliarity between closely related Vs.
hen possible, PCR ampliﬁcation products were se-
uenced to verify the appropriate speciﬁcity of the V
egion primer. RNA was isolated from canine periph-
ral blood utilizing the Qiamp RNA miniblood isola-
Bion kit (Qiagen, Valencia, CA). First-strand cDNA
as produced (50 L) using 400 U Superscript II or
lternatively Superscript III reverse transcriptase (In-
itrogen, San Diego; CA) and oligo(dT) primers. For
CR reactions (25 L total volume), 1 L of the
DNA reaction was added to wells of a 96-well PCR
late. Master mix containing Platinum Taq (1.25 U)
Invitrogen, Gaithersburg, MD), Mg buffer (15
M ﬁnal) and dNTPs (400 m each ﬁnal) was added
o each well using a multichannel pipettor. Subse-
uently 1 L of premixed V speciﬁc forward (In-
itrogen) and IRD700 labeled TCR reverse primers
MWG Biotech, High Point, NC) were added to the
ppropriate wells using a multichannel pipettor. The
rimers used in this study are shown in Table 1 Plates
ere covered with PCR plate sealers and reactions
ere run on a thermocycler using the program 94°C
5 seconds, 55°C 30 seconds, and 72°C 60 seconds,
or a total of 35 cycles. Four microliters of acrylamide
el loading buffer (0.05% bromphenol blue, 20 mM
DTA in formamide) were added to each well, and
amples were heated to 94°C for 5 minutes. Ampliﬁ-
ation products were subsequently loaded (0.8 L)
nto a 6% 25 cm acrylamide (Longranger, Cambrex,
alkersville, IN) sequencing gel and run on a Gene
eader 4200 DNA analyzer (LiCor, Lincoln, NE).
esults of the sequence run were converted into his-
ogram plots utilizing the NIH image gel peak analysis
eature [31].
For comparison of the TCR V repertoire be-
ween dogs, we have classiﬁed the spectratype proﬁles
nto three categories: polyclonal Gaussian, polyclonal
kewed, or oligoclonal [17]. Polyclonal Gaussian pro-
les have at least 6 peaks that have a Gaussian distri-
ution. Polyclonal skewed proﬁles have at least 6
eaks but with a shift of peak distribution off center.
able 1. Primer List
Primer Sequence (5=-3=) Size (bp)
V1 GATTTTTAGCCTTCTGTCC 156
V2 CCAGGGTCCCCGGTTTCTCA 224
V3.1 ACTGCCTCCGGTCGCTTCTCAC 169
V3.2 ACTGCCTTCTGGTCGCTTCTCAC 168
V3.3 ACTCTGCCTTGTATCTCTGTGCTA 89
V4 AGGGCCCGGAGTTTCTGGT 224
V6.1 CAACAATAAGGAACTCAT 213
V6.2 TCTACTTTAATCAGGGACTCAATC 200
V7 GCTGCTGCTCTACTACTATGAT 211
V9 GGCTGCTCTACTGGTCCTATAATA 214
V10 AGCCCCGAGAAAGGACACAGTTAT 277
V12 CAGCGGCCTCTACTTCTTGTGGTG 89
V13 ATGGGCCGAGGCTGATCTATTATT 221
V14 TGCAGAAGCCACCTACGAAAGT 190
V15 GCCCCGGGACGAGGAGTTGTATC 188
V16 TTTGGGCTACAGCTGATCTACTAC 160
V17 AGTCTACCAGCCTCTCACAG 107
V18 GTCTCCGCACGATTCTCA 183
C TCTCTGCTTCCGATGGTTCAA
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W. Vernau et al.1008ast, oligoclonal proﬁles have 4 or less peaks with 1
redominant peak. A representative example of each
f these proﬁles is illustrated in Figure 1.
ESULTS
one Marrow Transplantation
A total of 10 bone marrow transplanted XSCID
ogs were evaluated for their T cell diversity at vary-
ng times posttransplant. Table 2 describes the type of
ransplant, whole bone marrow or puriﬁed bone mar-
ow CD34 cells, the dogs received and the time
osttransplant at which the initial evaluation of their
cell repertoire was performed. The oldest three
ogs in this table (R743, X58, and R468) were also
valuated 3 years after the initial evaluation.
mmune Reconstitution
Prior to treatment, all XSCID dogs had the typical
SCID phenotype characterized by T cell lymphope-
ia with 0.5% of the peripheral blood lymphocytes
eing CD3 as determined by ﬂow cytometry. Figure
illustrates the kinetics of immune reconstitution in
he XSCID dogs transplanted dogs with either unfrac-
ionated bone marrow or puriﬁed bone marrow
D34 cells during the ﬁrst 6 months following
ransplantation. The absolute lymphocyte counts
Figure 2A) and proportion of peripheral T cells (Fig-
re 2B) had normalized by 2 months posttransplanta-
ion in both groups of dogs. At 2 months posttrans-
lantation, when the proportion of peripheral T cells
ere within normal range, over 90% of the peripheral
cells in both groups expressed the CD45RA (na-
ve) phenotype (Figure 2C), suggesting that they de-
eloped through a thymic-dependent pathway [16,32-
6]. During the initial T cell regeneration in both
roups of dogs the majority of the T cells express a
D4 phenotype as evidenced by the high CD4/CD8
atio compared to age-matched controls with the
D4/CD8 ratio decreasing to normal levels by 6
onths posttransplant (Figure 2D). The ability of
eripheral T cells to proliferate in response to the
onspeciﬁc T cell mitogen PHA was evaluated as a
igure 1. Classiﬁcation of TCR V spectratypes. Polyclonal
aussian distribution (A), polyclonal skewed distribution (B), and
ligoclonal distribution (C).easurement of T cell function. T cell function in *oth groups appeared normal by 2 months posttrans-
lant (Figure 2E). All the transplanted dogs developed
ormal levels of IgG-speciﬁc antibody following vac-
ination at 6 to 8 months posttransplant Figure 2F).
Table 3 illustrates the immunologic phenotype of
he transplanted dogs at the time their T cell reper-
oire was evaluated. All dogs had normal numbers of
eripheral T cells at the time of evaluation. The CD4/
D8 ratio remained normal (1.5) through 5.5 years
osttransplant, whereas dogs evaluated after 5.5 years
ad a CD4/CD8 ratio ranging from 0.3 to 0.4. This is
n contrast to normal dogs that maintain a normal
D4/CD8 ratio averaging 1.5 up through 9 years of
ge that is similar to the average CD4/CD8 ratio of
.5 in normal humans through 75 years of age [37-40].
he proportion of peripheral CD45RA (naïve) T
ells showed the typical age-related decrease from
85% through the ﬁrst 2 years posttransplant to 70%
t 5.5 years posttransplant; however, the proportion of
eripheral CD45RA T cells increased at the time of
nverted CD4/CD8 ratios.
CR V Diversity following Bone
arrow Transplantation
T cell diversity was evaluated by TCR V CDR3-
ize spectratyping, a method that measures the size
eterogeneity of the TCR hypervariable CDR3 re-
ion, in 10 XSCID dogs at varying times following
MT ranging from 4 months through 10.5 years post-
ransplant. Normal individuals possess complex and
iverse spectratypes that are characterized by a Gauss-
an distribution of multiple bands representing the
ifferent lengths of the respective CDR V-D-J re-
ions. XSCID dogs were not evaluated prior to trans-
lant because, at that time, there were 0.5% periph-
ral T cells. T cell diversity was also evaluated in
ormal dogs ranging from 2 to 7 years of age. Figure
illustrates the individual spectratypes for each of the
one marrow transplanted XSCID dogs at their initial
valuation and a representative 2-year-old and 7-year-
ld normal dog. Figure 4 illustrates the proportion of
pectratypes demonstrating a polyclonal Gaussian,
able 2. Type of and Age Post-BMT of Initial T Cell Repertoire
valuation
Dog Type of BMT Age Post-BMT*
1501 WBM 4 months
1503 WBM 4 months
212 WBM 4 months
1475 CD34 (5  106/kg) 6 months
1263 CD34 (20  106/kg) 1.5 years
1163 WBM 2 years
868 CD34 (35  106/kg) 3.5 years
743 CD34 (10  106/kg) 4.5 years
58 WBM 5.5 years
468 WBM 7.5 yearsAge post-BMT at which initial TCR V analysis was performed.
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T Cell Diversity in BMT XSCID Dogs 1009olyclonal skewed, or oligoclonal proﬁle in individual
ormal dogs of various ages and in transplanted XS-
ID dogs at various time points following BMT.
TCR V diversity in normal dogs remains poly-
lonal through at least 6 years of age, with 70% of
he spectratypes exhibiting a polyclonal Gaussian pro-
le. By 4 months post-BMT, when normal numbers
f CD45RA T cells and normal T cell function are
resent, the transplanted dogs show a normal, diverse
cell repertoire with 89% of the spectratypes ex-
ibiting a polyclonal Gaussian proﬁle. Between 2 and
.5 years posttransplant TCR V diversity showed
igure 2. Immunologic reconstitution in XSCID dogs following trans
ymphocyte counts (A), proportion of peripheral T cells (B), proportion
esponse following stimulation with PHA (E), and IgG speﬁcic antiboigns of decreasing as evidenced by a decrease in the droportion of polyclonal Gaussian proﬁles and the
ppearance of oligoclonal proﬁles, such that at 7.5
ears posttransplant 56% of the proﬁles were poly-
lonal Gaussian and 28% oligoclonal.
We had the opportunity to evaluate the TCR V
iversity in the three older transplanted dogs 3 years
ollowing the initial evaluation—7.5, 8.5, and 10.5
ears post-BMT. Figure 5 shows the individual spec-
ratypes of the 3 dogs at the initial evaluation and 3
ears later, whereas Figure 6 illustrates the proportion
f spectratypes demonstrating a polyclonal Gaussian,
olyclonal skewed, or oligoclonal proﬁle in these
ion with whole bone marrow or CD34 bone marrow cells. Absolute
heral CD45RA (naïve) T cells (C), CD4/CD8 ratio (D), proliferative
onse following immunization with tetanus toxoid (F).plantat
of peripogs. At the time of the second evaluation, all 3 dogs
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W. Vernau et al.1010ad CD4/CD8 ratios ranging from 0.3 to 0.4. Sub-
tantial changes in the TCR V diversity were ob-
erved in 2 of the dogs between the initial and second
valuation. For example, the proportion of polyclonal
aussian spectratypes decreased from 56% to 33% in
og R743 between 4.5 and 7.5 years posttransplant,
hereas the proportion of polyclonal skewed spectra-
ypes increased from 28% to 56%, and the proportion
f polyclonal Gaussian spectratypes decreased from
6% to 33% in dog R468 between 7.5 and 10.5 years
able 3. Immunologic Phenotype of the Transplanted Dogs at the Time
Dog Posttransplant* Lymphocytes
1501 4 months 7610
1503 4 months 6910
212 4 months 6080
1475 6 months 5230
1263 1.5 years 4800
1163 2 years 2840
868 3.5 years 3980
743 4.5 years 3210
7.5 years 1850
58 5.5 years 3360
8.5 years 3000
468 7.5 years 2650
10.5 years 2220
ormal dogs 7-9 years old 2625  812**
Time posttransplant at which TCR V analysis was performed.
Prroportion of CD3 T cells in the lymphocyte gate.
Proportion of CD3 T cells that are CD45RA.
*Mean 	 SD.
igure 3. TCR V spectratypes of normal dogs and XSCID dogs
ith an N and the bone marrow transplanted dogs designated with
umbers following the B represent the age in years following transplant.osttransplant and the proportion of polyclonal
kewed spectratypes increased from 17% to 50%. In
he third dog, X58, the decrease in the percentage of
olyclonal Gaussian TCR V families was smaller,
etween 5.5 and 8.5 years posttransplant.
ISCUSSION
The kinetics of T cell reconstitution was similar in
he XSCID dogs transplanted with histocompatible
V Analysis
CD3† CD4/CD8 CD45RA T Cells‡
72.6 3.8 97.1
81.2 4.2 98.7
77.5 3.6 96.4
80.6 4.4 92.9
81.4 2.1 88.5
77.2 1.7 86.7
79.1 1.5 80.6
78.5 1.8 71.2
94.9 0.4 91.1
88.6 1.4 70.2
96.8 0.3 92.7
90.2 0.7 86.8
94.0 0.3 96.7
82.1  5.3 1.5  0.2 73.4  3.1
ng bone marrow transplantation. The normal dogs are designated
numbers following the N represent age of the dog in years and theof TCRfollowi
B. The
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T Cell Diversity in BMT XSCID Dogs 1011hole bone marrow cells or highly puriﬁed histocom-
atible CD34 bone marrow cells, essentially a T
ell-depleted transplant, and is similar to that ob-
erved in human T cell-depleted histocompatible and
aploidentical transplants, or puriﬁed CD34 trans-
lants [7,16,34,41]. The delay in T cell reconstitution
n the XSCID dogs transplanted with histocompatible
hole bone marrow cells is in contrast to the rapid T
ell engraftment in human XSCID patients following
ransplantation of whole bone marrow cells from a
istocompatible donor because of peripheral expan-
ion of mature T cells in the graft. Although active T
ell depletion was not performed in our studies, the
igure 4. TCR V spectratyping in normal dogs and transplanted
SCID dogs. Each time point represents the summary results from
n individual dog. Results are expressed as percentage of total V
amilies representing a polyclonal Gaussian (PG), polyclonal
kewed (PS), or oligoclonal (O) phenotype. N-2, N-4, N-7 

ormal dogs at 2, 4, and 7 years of age.
igure 5. TCR V spectratypes of three XSCID dogs 3 years follo
osttransplant. Dog X58 was evaluated at 5.5 years and 8.5 year
osttransplant.ethod used to harvest the bone marrow for the
hole BMTs results in a ﬁnal preparation containing
1% mature T cells, compared to the 13% to 25%
ature T cells reported in aspirated human adult bone
arrow preparations [42-44]. Thus, our canine trans-
lants using whole bone marrow more closely resem-
le human T cell-depleted transplants than human
ransplants using whole bone marrow, and any T cell
econstitution depends upon active thymopoiesis.
There are similarities and differences between the
esults of this study in transplanted XSCID dogs and
oys [16,17]. In both the XSCID dogs and human
SCID patients, normal T cell diversity was evident
hen the number of CD45RA T cells had normal-
zed. Both showed a decrease in the complexity of
itial evaluation. Dog R743 was evaluated at 4.5 years and 7.5 years
ransplant. Dog R468 was evaluated at 7.5 years and 10.5 years
igure 6. TCR V spectratyping in 3 transplanted XSCID dogs at
nitial testing and 3 years later. Results are expressed as percentage
f total V families representing a polyclonal Gaussian (PG), poly-
lonal skewed (PS), or oligoclonal (O) phenotype.wing in
s postt
t
m
t
n
t
r
i
o
o
T
a
t
s
r
w
C
o
C
p
C
n
C
T
t
t
n
s
w
o
w
C
s
d
C
C
[
a
r
T
t
C
a
t
p
d
c
h
i
s
p
f
o
a
t
p
H
p
i
p
r
n
t
p
c
m
p
w
t
r
t
t
d
T
t
s
X
s
t
p
d
d
m
i
o
c
d
s
b
a
m
p
c
d
p
r
a
h
s
X
p
[
a
f
l
r
d
m
i
W. Vernau et al.1012heir T cell repertoire with age that appears to occur
ore rapidly than in normal individuals. At the time
ransplanted XSCID dogs and boys show a predomi-
ance of skewed or oligoclonal T cell repertoires,
here was a predominance of CD8 peripheral T cells
esulting in a CD4/CD8 ratio of 1.0. The predom-
nance of skewed or oligoclonal T cell spectratypes
bserved in the older XSCID boys was attributed to
ligoclonal expansion within the predominant CD8
cell population. T cell diversity within the CD4
nd CD8 T cell populations was not evaluated in the
ransplanted XSCID dogs; however, it is likely that a
imilar phenomenon is responsible for the observed
esults in the transplanted XSCID dogs. Although it is
ell documented that oligoclonal expansion occurs in
D8 T cells in elderly normal humans [45-47], the
verall T cell diversity remains high because the CD4/
D8 ratio remains normal and the CD4 T cell
opulation maintains a diverse repertoire [48].
In the human XSCID patients, the expanded
D8 T cells expressed a memory (CD45R0) phe-
otype that resulted in a ratio of CD45RA (naïve)/
D45R0 (memory) T cells of approximately 0.5.
he transplanted XSCID dogs showed an increase in
he proportion of CD45RA T cells to 90% at the
ime CD8 T cells became predominant. Although
ot directly examined in this study, we have previously
hown that in immune reconstituted XSCID dogs
ith CD4/CD8 ratios of 0.5, approximately 50%
f CD4 T cells express a CD45RA phenotype,
hereas 80% of the CD8 T cells express a
D45RA phenotype (Kennedy et al., manuscript
ubmitted). A possible explanation for this apparent
iscrepancy is that a subset of memory/activated
D8 T cells have been shown to express a
D8CD45RA phenotype [49,50]. Hamann et al.
49] have shown these cells are induced by antigens
nd evolve through extensive rounds of division that
esults in oligoclonality of their TCR V repertoire.
hus, it is likely that the CD8CD45RA T cells in
he transplanted XSCID dogs may represent memory
D8 T cells.
Although the transplanted XSCID dogs showed
n age-related decline in their T cell diversity similar
o that observed in the transplanted human XSCID
atients, this decrease appeared to be delayed in the
og. Signiﬁcant skewing of the T cell repertoire oc-
urred between 10 and 12 years posttransplant in the
uman XSCID patients, with the majority of V fam-
lies exhibiting a skewed phenotype. Predominance of
kewed V phenotypes was not observed in the trans-
lanted XSCID dogs until approximately 7.5 years
ollowing transplantation, the equivalent to a 45-year-
ld human based upon the comparison of biologic
ging between dogs and humans [51].
The transplants described in this study are similar
o those performed in human XSCID patients trans- wlanted in the neonatal period (28 days of age) [52].
uman XSCID patients transplanted in the neonatal
eriod show an increased success rate, more rapid
ncrease in the regeneration of the proportion of naïve
eripheral T cells and higher numbers of naïve pe-
ipheral T cells, and more rapid increase and higher
umbers of TRECs following transplantation than
hose XSCID patients transplanted past the neonatal
eriod. One could propose that the delay in the de-
line of T cell diversity observed in the XSCID dogs
ight be related to the fact that they were trans-
lanted as neonates. Although the T cell repertoire
as not examined in the human neonatal XSCID
ransplant study, transplantation in the neonatal pe-
iod did not improve the long-term T cell reconstitu-
ion because at 10 years posttransplant the patients
ransplanted in the neonatal period showed the same
ecline in the number of CD45RA T cells and
REC levels as that seen in patients transplanted after
he neonatal period. Because T cell diversity has been
hown to be directly correlated with TREC levels in
SCID patients following BMT [17], it is likely that
kewing of the T cell repertoire occurs at a similar
ime in neonatally transplanted patients as those trans-
lanted after the neonatal period.
An alternative, and more likely, explanation is the
ose of hematopoietic stem cells (HSC) used in the
og transplants. Although the dose of whole bone
arrow used in this study was comparable to that used
n human histocompatible transplants, the actual dose
f HSC, as determined by the number of CD34
ells, was signiﬁcantly greater because of the age of the
onor used in the dog studies. CD34 is expressed on a
ubpopulation of hematopoietic cells that contain
oth stem cells, presumably pluripotent stem cells,
nd early committed progenitors that are capable of
ultilineage engraftment in humans, mice, nonhuman
rimates, and, more recently, dogs [25,28,53-58]. It is
lear from a large body of clinical and experimental
ata that a population of cells within the CD34
opulation are both pluripotent and capable of self-
enewal. Although CD34 expression is currently used
s a surrogate marker for human and canine HSC, it
as been proposed that the T cell reconstitution ob-
erved in nonconditioned or nonmyeloablated human
SCID and Jak3 SCID patients results from T cell
rogenitors with little, if any, engraftment of HSCs
59]. This model is based upon the observation that
lthough 90% of the peripheral T cells in success-
ully transplanted nonconditioned or nonmyeloab-
ated XSCID and Jak3 SCID patients are donor-de-
ived following BMT, 10% of the patients possess
onor-derived B cells or myeloid cells [14,59]. This
odel predicts that there would be a gradual decline
n newly formed T cells after BMT in these patients,
hich is supported by the fact that TREC levels in
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T Cell Diversity in BMT XSCID Dogs 1013hese patients decline to very low levels by 10 to 12
ears posttransplant [16,59].
There may be qualitative differences in the num-
ers of infused HSC or committed lymphoid progen-
tors in the present experiment. All the donors in our
tudy were neonatal puppies, whereas, the majority of
uman donors are older siblings or adults. Aspirates of
uman adult bone marrow contain approximately 1%
o 2% CD34 cells, whereas the proportion of
D34 cells obtained by ﬂushing fetal bone marrow
s signiﬁcantly higher with up to 20% CD34 cells
54,60-62]. Similar age-related differences exist in the
roportion of CD34 cells in the dog. Canine adult
one marrow contains approximately 2% CD34 cells
28], whereas, the proportion of bone marrow CD34
ells in neonatal canine bone marrow ranges between
% and 14% [63]. Therefore, the use of neonatal
onors in our canine whole BMTs resulted in the
ransplantation of between 4- and 7-fold more CD34
ells and likely HSC than used in the similar human
ransplants. The dose of puriﬁed CD34 bone mar-
ow cells was similar to the dose of CD34 cells
ontained in the whole bone marrow grafts. We have
reviously reported that transplantation of noncondi-
ioned XSCID dogs with whole bone marrow or pu-
iﬁed CD34 cells does not result in donor myeloid
himerism, but, in contrast to human XSCID patients,
90% of successfully transplanted XSCID dogs dem-
nstrate up to 20% donor B cell chimerism [23,25].
he transplantation of signiﬁcantly higher numbers of
D34 bone marrow cells may result in the engraft-
ent of a more immature lymphoid progenitor that
ould result in a more sustained T cell regeneration.
his hypothesis can be tested by transplanting XSCID
ogs with similar doses of CD34 bone marrow cells
s routinely used in transplantation of XSCID boys.
In conclusion, XSCID dogs develop a normal T
ell repertoire following nonablative BMT similar to
hat observed in XSCID boys following nonablative
MT. However, in contrast to transplanted XSCID
oys who show a signiﬁcant decline in their T cell
iversity by 10 to 12 years following BMT, trans-
lanted XSCID dogs maintain a polyclonal, diverse T
ell repertoire through midlife.
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